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Abstract
Background: To determine the cost-effectiveness of strategies of preferred antibiotic treatment with beta-lactam/
macrolide combination or fluoroquinolone monotherapy compared to beta-lactam monotherapy.
Methods: Costs and effects were estimated using data from a cluster-randomized cross-over trial of
antibiotic treatment strategies, primarily from the reduced third payer perspective (i.e. hospital admission
costs). Cost-minimization analysis (CMA) and cost-effectiveness analysis (CEA) were performed using linear
mixed models. CMA results were expressed as difference in costs per patient. CEA results were expressed
as incremental cost-effectiveness ratios (ICER) showing additional costs per prevented death.
Results: A total of 2,283 patients were included. Crude average costs within 90 days from the reduced third
payer perspective were €4,294, €4,392, and €4,002 per patient for the beta-lactam monotherapy, beta-lactam/
macrolide combination, and fluoroquinolone monotherapy strategy, respectively. CMA results were €106 (95% CI €-697
to €754) for the beta-lactam/macrolide combination strategy and €-278 (95%CI €-991 to €396) for the fluoroquinolone
monotherapy strategy, both compared to the beta-lactam monotherapy strategy. The ICER was not statistically
significantly different between the strategies. Other perspectives yielded similar results.
Conclusions: There were no significant differences in cost-effectiveness of strategies of preferred antibiotic
treatment of CAP on non-ICU wards with either beta-lactam monotherapy, beta-lactam/macrolide combination
therapy, or fluoroquinolone monotherapy.
Trial registration: The trial was registered with ClinicalTrials.gov, number NCT01660204, on May 2nd, 2012.
Keywords: Beta-lactam macrolide, Fluoroquinolone, Cost-effectiveness, Community acquired pneumonia
Background
Community-acquired pneumonia (CAP) is an important
reason for hospitalization worldwide [1–3]. It has been
estimated that the total costs associated with CAP
amount to approximately 11 billion euros annually in
Europe, with approx. 5 billion euros accounting for in-
hospital CAP costs [1]. In the Netherlands there are an
estimated 25,000-36,000 hospital admissions for CAP
each year, [4] with an estimated total costs of about 100
to 178 million euro annually [5, 6]. The intramural costs
are mainly determined by the length of hospitalization
and site of care (medical ward or intensive care unit,
ICU) [5, 6].
In choosing the optimal antibiotic treatment strategy
for CAP, effectiveness, cost-effectiveness and ecological
effects of antibiotics should be taken into account.
Optimally, this would consist of a strategy associated
with the best patient outcome at the lowest price and
* Correspondence: d.f.postma@umcutrecht.nl
†Equal contributors
1Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, Utrecht, The Netherlands
2Department of Internal Medicine and Infectious Diseases, University Medical
Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van Werkhoven et al. BMC Infectious Diseases  (2017) 17:52 
DOI 10.1186/s12879-016-2179-6
with least selective pressure for antibiotic resistance.
The three treatment strategies most widely used are
beta-lactam monotherapy, beta-lactam/macrolide com-
bination therapy, and fluoroquinolone monotherapy.
From an ecological perspective beta-lactam monother-
apy is preferred over beta-lactam/ macrolide combin-
ation therapy, and fluoroquinolone monotherapy, since
the latter two drug classes have been associated with
resistance development during treatment [7, 8].
In a cluster-randomized cross-over trial of patients
hospitalized with CAP to non-ICU wards, a strategy of
beta-lactam monotherapy was non-inferior to beta-
lactam/macrolide combination therapy, and fluoroquino-
lone monotherapy in terms of all-cause day-90 mortality
(CAP-START study) [9]. The quinolone monotherapy
strategy was associated with a shorter length of intraven-
ous treatment, but this was not reflected in a statistically
significant shorter length of stay. In the current study,
we set out to conduct a cost-minimization analysis of
these different antibiotic strategies and a cost-




The Community-Acquired Pneumonia Study on the
initial Treatment with Antibiotics of Lower Respiratory
Tract Infections (CAP-START, http://clinicaltrials.gov/
show/NCT01660204) was a cluster-randomized cross-
over trial that was performed in seven hospitals in the
Netherlands between February 2011 and August 2013.
Details of the study design, enrolment, and clinical out-
comes have been published previously [9, 10]. In short,
three strategies were compared in which one class or
combination of antibiotics (beta-lactam monotherapy,
beta-lactam/macrolide combination therapy or fluoro-
quinolone monotherapy) was the preferred empirical
treatment for adult patients hospitalized to non-
intensive care unit (ICU) wards with a clinical diagnosis
of CAP. Hospitals were randomized to a sequence of
consecutive periods of 4 months, in each of which
one of the strategies were applied. Deviations from
the preferred empirical treatment for medical reasons
were allowed, e.g. because of contra-indications,
allergy to the preferred regimen, or a suspected
pathogen not covered by the preferred regimen. Phy-
sicians were encouraged to complete the preferred
empirical treatment unless for a medical reason, e.g.
insufficient recovery or deterioration of the patient, or
detection of a pathogen for which targeted antibiotic
treatment was initiated. Based on an intention-to-
treat principle, inclusion of patients was independent
of compliance with the strategy, which allowed us to
assess the effect of the strategy as a whole.
Effects
For health outcomes we used 30- and 90-day all-cause
mortality, which have been reported previously [9]. Mor-
tality status at day 90 was recorded from the medical
charts in patients that died during hospitalization, and
patients that had visited the hospital after day 90 (e.g. in
an out-patient clinic). The status of all other patients,
except in one hospital, was checked electronically in the
municipal personal records database, which is based on
the citizen service number, date of birth and name. In
the one hospital without electronic access to this data-
base, research nurses contacted the general practitioner
of each patient with an unknown status. In the
Netherlands, every inhabitant is registered with a single
general practitioner, who is routinely informed about
important medical affairs.
Cost of illness
Data on healthcare resource utilization during
hospitalization, e.g. hospital days, interventions, and
medication (see Additional file 1: Table S2 for a
complete overview), were derived from the medical
records by trained research nurses using a predefined
clinical record form. For other resources, patients
were asked to complete a questionnaire on the 28th
day after admission. This 28th day questionnaire
included questions on post-discharge healthcare use
such as nursing home admission, general practitioner
and specialist consultations, patient costs (e.g. travel
costs), and the number of days absent from paid and
unpaid work for both patients and their caregivers.
We defined caregivers as adult persons taking ab-
sence from paid or unpaid work in order to take care
of a sick person.
Direct healthcare costs (DHC), direct non-healthcare
costs (DNHC) - also referred to as patient costs -, and
productivity losses (i.e. indirect non-healthcare costs-
INHC) were considered in the current study. In accord-
ance with the current Dutch guidelines for health
economic evaluations, this study did not consider indir-
ect healthcare costs [11, 12]. Indirect healthcare costs
would comprise the future savings in healthcare costs in
the life years lost due to premature death. DHC were
composed of healthcare costs related to hospitalization,
e.g. days admitted to non-ICU wards, ICU days with and
without mechanical ventilation, medical interventions,
antibiotic use, other medication use, and post-discharge
healthcare consumption. In the DNHC category, travel
costs to a general practitioner (GP), to a hospital, or
over-the-counter medication were considered. Productiv-
ity losses were estimated for non-fatal CAP cases by
multiplying self-reported sick leave from paid and unpaid
work with the corresponding age and gender specific unit
prices as reported in Additional file 1: Table S1. For fatal
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cases younger than 65 years, two approaches were
used: the friction and the human capital approach.
The friction approach, recommended in Dutch guide-
lines, takes into account the productivity loss from
paid work due to case fatality for a period of 23 weeks
from the date of admission [11, 12]. In the human
capital approach, productivity losses from work due
to case fatality up to the age of retirement were con-
sidered, leading to higher costs due to productivity
loss for deceased patients under 65 years of age.
Costs were estimated by multiplying resources used
with their corresponding unit cost prices. Additional
file 1: Table S1 depicts unit cost prices for all DHC,
DNHC, and INHC used in the analyses. All costs are
expressed in 2012 euros and, if necessary, updated
using Dutch consumer price indexes [4].
Two time horizons of 30 and 90 days were used for
the economic evaluation, in accordance with the time
horizons used for the effects under study, i.e. 30-day and
90-day mortality [9]. Hospital and nursing home admis-
sion costs were calculated until discharge or until the
time horizon, whichever came first. For productivity
losses from case-fatality, deaths falling within the defined
time horizon were used, but, as explained previously,
costs were extended to 23 weeks using the friction ap-
proach [11, 12], and to retirement age using the human
capital approach, respectively. Discounting was only
applied for productivity losses longer than 1 year (i.e.
the human capital approach), using a 3% annual dis-
count rate [13]. As in the primary analysis of clinical
outcomes, the 90-day time horizon was considered
for the primary analysis.
Economic evaluation
Cost-minimization analysis (CMA) and cost-
effectiveness analysis (CEA) were conducted using four
different perspectives. The “reduced” third payer per-
spective included only DHC of the CAP hospitalization.
This perspective constituted the primary analysis of
medical records, and as such healthcare utilization data
during admission, were available for all patients. The
“full” third payer perspective (referred hereafter as third
payer perspective) included both DHC during admission
and post-discharge. The societal perspective considered
all three categories (i.e. DHC, DNHC and INHC). Two
approaches were used here, the friction and the human
capital approach, as explained previously.
The beta-lactam monotherapy strategy was considered
the reference arm, as this is considered the first choice
treatment for patients hospitalized with CAP to non-
ICU wards in the Netherlands [14]. As the primary out-
come of the CAP-START trial, i.e. prevented deaths per
treated person, was not statistically significantly different
between the strategies [9], we conducted a CMA,
assessing the incremental costs per treated case. Add-
itionally, because small effects on clinical outcomes
could not be excluded, a CEA was conducted showing
the incremental costs (or savings) of the net effect (i.e.
number of deaths prevented), expressed as incremental
cost-effectiveness ratio (ICER) showing additional costs
per prevented death.
Data analysis
Crude average costs were calculated for each antibiotic
treatment strategy. For calculating incremental costs, we
adjusted for the cluster-randomized design of the study,
by using a mixed-effects linear regression analysis, with
a random intercept for each cluster-period of 4 months,
and fixed effects for hospital and treatment arm. A ran-
dom intercept is used in mixed-effect models to allow
for dependence of observations within one cluster [15].
For cost-minimization and cost-effectiveness analyses,
differences in mortality (i.e. the incremental effect) were
assessed similarly using a mixed-effects logistic regres-
sion analysis. We performed bootstrapping with 2,000
samples to obtain confidence intervals. For missing
values, five imputations were performed in each boot-
strapped dataset. In each of the imputed datasets, the
costs and effects were compared between the treatment
strategies using the aforementioned mixed-effects
models. Incremental costs and effects were averaged
over these 5 imputations, again resulting in 2,000 esti-
mates of incremental costs and effects. From these, we
derived incremental costs and effects which were pre-
sented as cost-effectiveness plots. 95% confidence inter-
vals were derived from these estimates using the
quantile method. Significance for cost-minimization and
cost-effectiveness was defined as a 95% confidence inter-
val not covering the null effect.
Results
Patient, data collection, and missing data
In total 656, 739, and 888 patients were included
during the beta-lactam, beta-lactam/macrolide and
fluoroquinolone strategies. Age, gender, and comor-
bidities had similar distributions in the three treat-
ment arms (Table 1). Inclusion rates, strategy
adherence, and reasons for protocol deviations and
switches have been described previously [9]. Response
rates for the self-reported 28th day questionnaire were
comparable in all three treatment arms (42.1%, 34.2%,
and 42.3% for beta-lactam monotherapy, beta-lactam/
macrolide combination, and fluoroquinolone mono-
therapy strategy respectively).
In total, 2.1 and 6.6% of data points from the medical
records and received 28th day questionnaires, respect-
ively, were missing.
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Cost of illness and economic evaluation
Crude (i.e. not adjusted for the cluster-randomized
cross-over design) average costs within 90 days from the
reduced third payer perspective (i.e. hospitalization
costs) were €4,294 (95% confidence interval, CI
€3,782 to €4,952) per patient for the beta-lactam
monotherapy strategy, €4,392 (95% CI €4,062 to
€4,760) per patient for the beta-lactam/macrolide
combination strategy, and €4,002 (95% CI €3,725 to
€4,341) per patient for the fluoroquinolone mono-
therapy strategy (Fig. 1). For the CMA using the
reduced third payer perspective within the 90-day
time horizon, estimated incremental costs, adjusted
for cluster and period effects using a mixed-effects
model, were €106 (95% CI -€697 to €754) per pa-
tient for the beta-lactam/macrolide combination
strategy and -€278 (95%CI -€991 to €396) for the
fluoroquinolone monotherapy strategy, a positive
number indicating higher costs as compared to the
beta-lactam monotherapy strategy.
For the beta-lactam/macrolide strategy compared to
the beta-lactam strategy, using the reduced third
payer perspective and the 90-day time horizon, 57.8%
of the bootstrap results was in the north-west quad-
rant (i.e. positive incremental costs, the beta-lactam/
macrolide strategy was more costly than the beta-
lactam strategy, and negative incremental effects, the
beta-lactam/macrolide strategy prevented fewer deaths
than the beta-lactam strategy, thus beta-lactam domi-
nates the beta-lactam/macrolide strategy), 3.3% was in
the north-east quadrant (i.e. “positive” incremental
costs and a positive incremental effect), 35.2% was in
the south-west quadrant (i.e. negative incremental
costs or cost-savings and a negative incremental
effect), and 3.6% was in the south-east quadrant (i.e.
negative incremental costs and a positive incremental
effect), with the point estimate for the ICER in the
north-west quadrant (Fig. 2a). For the fluoroquinolone
strategy compared to the beta-lactam strategy, using
the same perspective and time window, 11.6% was in
the north-west quadrant, 10.2% in the north-east
quadrant, 35.3% in the south-west quadrant, and
43.0% was in the south-east quadrant, with the point
estimate for ICER in the south-east quadrant (Fig. 2c).
Thus, the 95% confidence interval of the ICER ranged
from being dominated (positive incremental costs and
negative incremental effect) to cost-saving (negative
incremental costs or savings and positive incremental
effects or more prevented deaths) for both
comparisons.
Similar results for costs, CMA, and CEA were
obtained for the third payer perspective and for the
societal perspective taking the friction approach
(Fig. 2, Additional file 1: Figure S1, Figure S2, and
Table S3), as well as for the 30-day time horizon for
these three perspectives. The societal perspective
with human capital approach had large confidence
intervals for costs, for both time horizons, leading to
uninterpretable results for both CMA and CEA
(Additional file 1: Figure S3 and Table S3).







Median age (IQR) 70.6 (60.6–79.4) 70.7 (59.1–80.3) 71.0 (59.6–79.4)
Male gender 381 (58.1%) 431 (58.3%) 505 (56.9%)
Elderly home 32 / 644 (5.0%) 38 / 727 (5.2%) 41 / 878 (4.7%)
Hospitalization past 12 months 271 / 653 (41.5%) 298 / 722 (41.3%) 351 / 881 (39.8%)
Median number of comorbidities (IQR) a 1 (0–2) 1 (0–2) 1 (1–2)
Immunocompromised b 147 (22.4%) 173 (23.4%) 213 (24.0%)
Median CURB-65 score (IQR) d 1 (1–2) 1 (1–2) 1 (1–2)
Day-28 questionnaire received 276 (42.1%) 253 (34.2%) 376 (42.3%)
Reports paid work 51 / 246 (20.7%) 45 / 233 (19.3%) 78 / 342 (22.8%)
Reports volunteer work 23 / 245 (9.4%) 32 / 234 (13.7%) 35 / 340 (10.3%)
Data are reported as N (%) unless otherwise indicated. IQR: inter quartile range
a Reported comorbidities include chronic cardiovascular disease, heart failure, cerebrovascular disease, asthma, COPD, other chronic pulmonary disease, HIV/AIDS,
diabetes mellitus, haematological malignanciesc, solid organ malignanciesc, chronic renal failure requiring dialysis, nephrotic syndrome, organ or bone marrow
transplantation, alcoholism, chronic liver disease and functional or anatomic asplenia
bPatients were categorized as immunocompromised if any of the following conditions applied: HIV/AIDS, haematological malignancies#, solid organ malignanciesc,
chronic renal failure requiring dialysis, nephrotic syndrome, organ or bone marrow transplantation, or receipt of immunosuppressive therapy
(for corticosteroids this required at least 0.5 mg/kg/day prednisolone or equivalent dosage for a minimum of 14 days)
c Having received or been eligible for chemotherapy or radiotherapy in the past 5 years
d The CURB-65 score is calculated by assigning 1 point each for confusion, uraemia (blood urea nitrogen ≥20 mg per deci- liter), high respiratory rate (≥30 breaths
per minute), low systolic blood pressure (<90 mm Hg) or diastolic blood pres- sure (≤60 mm Hg), and an age of 65 years or older, with a higher score indicating a
higher risk of death within 30 days
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Discussion
In these analyses, we have demonstrated that the differ-
ences in costs associated with either of three preferred
empirical antibiotic treatment strategies (i.e., beta-lactam
monotherapy, beta-lactam/macrolide combination ther-
apy, or fluoroquinolone monotherapy) for patients
hospitalized for community-acquired pneumonia did not
reach statistical significance. Together with non-
inferiority of the beta-lactam monotherapy strategy for
day-90 mortality [9] and the perceived preference of
beta-lactam monotherapy from an ecological perspec-
tive, the current analysis supports the use of beta-lactam
monotherapy as preferred empirical treatment for these
patients.
This is the first comparison of costs and cost-
effectiveness for different preferred antibiotic treatment
strategies in patients hospitalized with CAP. Our study
has several strengths. First, because this was a pragmatic
trial, where patients were included during strategy
periods regardless of the actual antibiotics used, the
intention-to-treat analysis of our study is well
generalizable to daily clinical practice. All patients that
received antibiotic treatment for a working diagnosis of
CAP and who were hospitalized to a non-ICU medical
ward, were eligible. Second, the cluster-randomized
design allowed the immediate start of the allocated anti-
biotic treatment because individual randomization was
not needed. This minimizes effects of other antibiotics
prescribed in the Emergency Departments before study
randomization. Third, because of the cross-over design,
all hospitals applied all three strategies, thus minimizing
confounding bias. As a result, baseline characteristics of
the three strategies were very comparable. Fourth, we
have collected comprehensive data on antibiotic treat-
ment and medical procedures that allowed us to esti-
mate hospitalization costs per patient. Using 2,000
bootstrapping samples and five imputations per sample,
we were able to provide robust estimates and confidence
intervals for the different cost categories. Our estimated
costs per CAP admission are in line with previously pub-
lished data from the Netherlands [5, 6]. Fifth, different
economic viewpoints were pursued in the current ana-
lysis. The (reduced) third payer perspective and the soci-
etal perspective taking the friction approach all gave the
same direction and magnitude of effect. The large confi-
dence intervals observed in the societal perspective with
human capital approach was due to the low number of
fatal cases under 65 years of age and due to working
status being unknown for unreturned 28th day question-
naires. This led to unstable imputation of working sta-
tus, since these variables also interact i.e. the proportion
of returned questionnaires was lower for patients that
had died at day 90, thus increasing confidence intervals.
Our approach had certain limitations. We had limited
data on medication use other than antibiotics. Although
it seems unlikely that one of the antibiotic treatment
strategies would be associated with other patterns of
non-antibiotic medication use, if so, we may have
slightly underestimated the costs. 28th day question-
naires, used for DNHC and INHC estimation, were
returned by approximately 40% of the participants. We
used multiple imputation to deal with missing data
because response to the 28th day questionnaire was obvi-
ously dependent on clinical outcome and was related to
baseline characteristics (e.g. dependency in activities of
daily living or hospitalizations in the previous year). This
Fig. 1 Mean costs per patient. a 90-day time horizon. b 30-day time
horizon. Legend: Mean costs per patient for the three treatment
strategies taking four different perspectives and applying a 90-day
(a) and 30-day (b) time horizon. Point estimates and confidence
intervals are generated using the 50th, 2.5th and 97.5th percentiles
of 2,000 bootstrapping samples. Exact numbers are given in
Additional file 1: Table S3
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may have increased uncertainty for the third payer and
societal perspectives, and it certainly did for the societal
perspective with human capital approach, as explained
previously.
The number of days on intravenous antibiotic treat-
ment was significantly lower during the fluoroquinolone
monotherapy strategy (hazard ratio for time to switch to
oral treatment 1.29, 95% CI 1.15–1.46) [9]. This was
fully explained by the larger proportion of patients start-
ing with oral treatment from the day of admission, des-
pite the similar baseline characteristics between the
different strategies, and can, therefore, not be attributed
to a faster clinical response. The known high bioavail-
ability of oral fluoroquinolones [16] may have stimulated
Fig. 2 Cost-effectiveness plots from a reduced third payer perspective. a Beta-lactam/macrolide strategy vs. beta-lactam strategy-90-day time
horizon. b Beta-lactam/macrolide strategy vs. beta-lactam strategy-30-day time horizon. c Fluoroquinolone monotherapy strategy vs. beta-lactam
strategy-90-day time horizon. d Fluoroquinolone monotherapy strategy vs. beta-lactam strategy-30-day time horizon. Legend: Grey points represent
incremental costs and incremental effects of 2,000 bootstrapping samples for the beta-lactam/macrolide combination strategy compared
to the beta-lactam monotherapy strategy within 90 (a) and 30 (b) days of admission, and for the fluoroquinolone monotherapy strategy
compared to the beta-lactam monotherapy strategy within 90 (c) and 30 (d) days of admission. The black points and curves represent
the point estimates and the 95% confidence ellipses. Proportions in each quadrant indicate the proportion of bootstrap samples in that
quadrant. Point estimates in the north-west quadrant are in favour of the beta-lactam monotherapy strategy; point estimates in the south-east quadrant
are in favour of the other strategy. Exact point estimates and 95% confidence intervals for incremental costs and incremental effects are
given in Additional file 1: Table S3
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physicians to directly start with oral antibiotics and this
may have contributed to the more favourable point esti-
mate of difference in costs seen in the fluoroquinolone
monotherapy period. Whether the same proportion of
patients could start with oral beta-lactam monotherapy
without compromising patient outcome remains to be
elucidated.
In an open-label randomized controlled trial from
Switzerland, beta-lactam monotherapy was not non-
inferior to beta-lactam/macrolide combination therapy
in establishing clinical stability after seven days of
antibiotic treatment [17]. This study was not designed
to determine non-inferiority for day-30 or day-90
mortality, and there were no statistically significant or
clinically relevant differences in outcome between
both study arms. Time to clinical stability was not
determined in our study, however, length of stay was
significantly longer for the beta-lactam/macrolide
combination strategy, and consequently also the costs
per patient were higher, although not statistically sig-
nificant. This seemingly opposite finding might in
part be explained by the maximized adherence to the
allocated antibiotic, i.e. the strict criteria for switching
antibiotic treatment, which could only have disadvan-
taged the beta-lactam monotherapy arm in the Swiss
study. The current analysis shows that any benefit of
beta-lactam/macrolide combination treatment on time
to clinical stability, if present, does not lead to cost
reduction.
Generalizability of the estimated costs may depend
on several factors, the most important of which are
the duration of hospitalization, ICU admission, the
length of intravenous and oral antibiotics, and post
discharge patterns of healthcare use. Although the
actual reported costs are obviously specific for the
Netherlands, the relative differences in costs for medi-
cation are comparable internationally [18, 19]. As the
generalizability of clinical outcome may depend on
the proportion of CAP caused by pathogens not cov-
ered by beta-lactam monotherapy, as discussed previ-
ously [9], we think that the cost-efficacy will be
similar in most regions with comparable etiology.
Conclusions
In conclusion, there is no significant difference in cost-
effectiveness of a strategy of preferred beta-lactam
monotherapy compared to beta-lactam/macrolide com-
bination therapy or fluoroquinolone monotherapy for
the empirical antibiotic treatment of CAP in non-ICU
wards. Together with the preference of narrow-spectrum
antibiotics from an ecological perspective, these data
support the use of beta-lactam monotherapy as pre-
ferred empirical treatment for patients hospitalized with
community-acquired pneumonia.
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